Navigation Links
Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
Date:4/1/2008

European Medicines Agency (EMEA) Grants Orphan Drug Status for the

Treatment of Spina Bifida

EAST NORRITON, Pa., April 1 /PRNewswire/ -- Tengion Inc. announced today that the European Medicines Agency (EMEA) and the European Commission (EC) have formally designated Tengion's autologous urothelial and smooth muscle cells -- the Neo-Bladder Augment(TM) -- as an Orphan Medicinal Product for the treatment of spina bifida.

This Orphan Medicinal Product Designation qualifies Tengion and its Neo- Bladder Augment for EMEA regulatory incentives, including eligibility for protocol assistance and possible exemptions or reductions of certain regulatory fees. Orphan Product designation also enables the Neo-Bladder Augment to qualify for 10 years of marketing exclusivity in the EU upon marketing approval.

In accordance with directives set forth by the European Commission, EMEA's Committee for Orphan Medicinal Products (COMP) agreed that Tengion's Autologous Neo-Bladder Construct meets the criteria for being designated as an EU Orphan Medicinal Product, for the treatment of spina bifida. Spina bifida is a debilitating illness that frequently results in neurogenic bladder. Although satisfactory methods of treatment for the neurogenic bladder have been authorized by EMEA, justifications have been provided that the Neo- Bladder Augment may be of significant clinical benefit to those patients with spina bifida who suffer from neurogenic bladder and warrant surgical intervention for their condition.

"We are extremely pleased that EMEA and the European Commission has recognized the Neo-Bladder Augment's potential to significantly improve the treatment of neurogenic bladder in spina bifida patients -- a critically underserved patient population," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "We look forward to continuing to work with the EMEA, as we are with the U.S. Food and Drug Administration, to determine the most effective and efficient regulatory path forward for our neo-organs and neo-tissues."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo- organ or neo-tissue that is designed to harness an individual's ability to regenerate specific organ tissue, catalyzing the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Appoints Jeff Randall to Board of Directors
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
4. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
6. Human Pheromone Sciences Announces Quarterly and Full Year Results
7. Dragon Pharma announces 2007 full year financial results
8. Genaera Corporation Announces 2007 Financial Results
9. Genmab Announces Year End 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):